865 F.3d 29
1st Cir.2017Background
- Relators (surgeons Nargol and Langton) brought a qui tam suit under the FCA alleging DePuy marketed the Pinnacle metal-on-metal (MoM) hip device with false statements and sold defectively manufactured units that deviated from the FDA-approved specifications.
- DePuy obtained 510(k) clearance in 2000 by asserting substantial equivalence to an earlier device (ASR); Relators allege DePuy misrepresented safety/effectiveness to the FDA and to physicians.
- Two manufacturing-defect theories: (1) heads/liners out-of-spec diametrical clearances (too tight) and (2) excessive surface roughness on the taper/trunnion; Relators contend large percentages of devices were nonconforming and failure rates were much higher than represented.
- Relators alleged both: (A) fraud in securing/maintaining FDA approval (design-defect theory), and (B) palming off latently defective, nonconforming units (manufacturing-defect theory) that led providers to seek government reimbursement.
- The district court dismissed the complaint under Rules 9(b) and 12(b)(6) for failure to plead particularized false claims; DOJ declined to intervene. On appeal the First Circuit reviewed de novo.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FCA claims can rest on alleged misrepresentations to the FDA about device design that secured 510(k) clearance | Relators: DePuy misled FDA about design/safety; those misstatements caused false claims and were material | DePuy: FDA clearance remained in place; FDA’s inaction breaks causation/materiality; relators can’t relitigate FDA approval via FCA | Held: Dismissed — claims premised on fraud-on-the-FDA/design-defect theory fail (D'Agostino principle; materiality/causation lacking when FDA, after notice, did not withdraw approval) |
| Whether FCA liability attaches where manufacturer knowingly sold devices that materially deviated from the FDA-approved specifications (palming off nonconforming units) | Relators: DePuy sold many nonconforming Pinnacle units to providers, who then sought government reimbursement | DePuy: Relators failed to plead particularized false claims showing reimbursement was sought for defective units | Held: Reversed in part — manufacturing-defect (palming off) theory survives for indirect claims because complaint alleged statistical and transactional indicia sufficient under the more flexible Rule 9(b) standard |
| Rule 9(b) particularity standard for indirect (causing third parties to submit) FCA claims | Relators: More flexible pleading standard applies; statistical and scheme-level facts can suffice without itemizing claims | DePuy: Karvelas/Karvelas-type particulars required; relators provided insufficient claim-level detail | Held: The court applied Duxbury/Grubbs flexibility — alleged scheme, sales volume, market share, and exemplar claim created a strong inference that false claims were submitted (sufficient for federal and New York indirect claims) |
| Whether district court abused discretion by denying leave to amend | Relators: Could add transactional particulars to cure pleading defects | DePuy: Amendments would be futile; core defects (FDA-based claims and out-of-state allegations) remain | Held: Affirmed — denial of leave to amend was not an abuse; proposed amendments would be futile or redundant for the dismissed claims |
Key Cases Cited
- United States ex rel. D'Agostino v. ev3, Inc., 845 F.3d 1 (1st Cir. 2016) (FCA claims premised on fraudulent procurement of FDA approval are implausible where FDA, after notice, did not withdraw approval)
- Universal Health Servs., Inc. v. United States, 136 S. Ct. 1989 (2016) (FCA materiality standard is demanding; government payment despite knowledge strongly indicates nonmateriality)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001) (FDA possesses tools to police misrepresentations to the agency; federal regulation/approval central to causation analysis)
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) (explaining differences in FDA premarket review pathways; 510(k) relies on substantial equivalence)
- United States ex rel. Duxbury v. Ortho Biotech Prods., L.P., 579 F.3d 13 (1st Cir. 2009) (applies a more flexible Rule 9(b) standard for indirect FCA claims where scheme-level facts and representative examples can show that claims were submitted)
- Karvelas v. Melrose-Wakefield Hosp., 360 F.3d 220 (1st Cir. 2004) (Rule 9(b) requires particularized transactional details for fraud-based claims, though not a rigid checklist)